Seminars in Hematology
Volume 43, Issue 2 , Pages 107-117 , April 2006

Allogeneic Transplantation for the Elderly Patient With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

  • Marcos de Lima

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marcos de Lima, MD, Associate Professor of Medicine, Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77033
    • ,
  • Sergio Giralt

References 

  1. Bortz W . Biological basis of determinants of health . Am J Public Health . 2005;95:389–392
  2. SEER: Surveillance, Epidemiology and End Results (SEER). SEER CANCER GOV (accessed on August, 2005)
  3. Godwin J , Smith T . Acute myeloid leukemia in the older patient . Crit Rev Oncol Hematol . 2003;48S:17–26
  4. Kelly L , Gilliland DG . Genetics of myeloid leukemias . Annu Rev Genomics Hum Genet . 2002;3:179–198
  5. Rossi D , Bryder D , Zahn J , Ahlenius H , Sonu R , Wagers A . Cell intrinsic alterations underlie hematopoietic stem cell aging . Proc Natl Acad Sci U S A . 2005;102:9194–9199
  6. Appelbaum FR , Rowe JM , Radich J , Dick JE . Acute myeloid leukemia . Hematology (Am Soc Hematol Educ Program) . 2001;62–86
  7. de Lima M , Strom SS , Keating M , Kantarjian H , Pierce S , O’Brien S , et al.   Implications of potential cure in acute myelogenous leukemia (Development of subsequent cancer and return to work) . Blood . 1997;90:4719–4724
  8. de Lima M , Ghaddar H , Pierce S , Estey E . Treatment of newly diagnosed acute myelogenous leukemia in-patients age 80 years and above . Br J Haematol . 1996;93:89–95
  9. Giralt S , Anagnostopoulos A , Shahjahan M , Champlin R . Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes . Semin Hematol . 2002;39:57–62
  10. Kolb HJ , Schattenberg A , Goldman JM , Hertenstein B , Jacobsen N , Arcese W , et al.   Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients . Blood . 1995;86:2041–2050
  11. Champlin R , Khouri I , Anderlini P , de Lima M , Hosing C , McMannis J , et al.   Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications . Oncology (Williston Park) . 2003;17:94–100
  12. Khouri IF , Lee MS , Saliba RM , Jun G , Fayad L , Younes A , et al.   Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma . J Clin Oncol . 2003;21:4407–4412
  13. Maris M , Storb R . The transplantation of hematopoietic stem cells after non-myeloablative conditioning (A cellular therapeutic approach to hematologic and genetic diseases) . Immunol Res . 2003;28:13–24
  14. van Besien K , Artz A , Stock W . Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? . Leukemia . 2005;19:31–33
  15. Couriel DR , Saliba RM , Giralt S , Khouri I , Andersson B , de Lima M , et al.   Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation . Biol Blood Marrow Transplant . 2004;10:178–185
  16. Sorror M , Maris M , Diaconescu R , Storb R . Lessened severe graft-versus-host after “minitransplantations” . Blood . 2005;105:2614
  17. Sorror ML , Maris MB , Storer B , Sandmaier BM , Diaconescu R , Flowers C , et al.   Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning (Influence of pretransplantation comorbidities) . Blood . 2004;104:961–968
  18. Corradini P , Zallio F , Mariotti J , Farina L , Bregni M , Valagussa P , et al.   Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advance hematologic malignancies . J Clin Oncol . 2005;23:6690–6698
  19. Baron F , Maris MB , Sandmaier BM , Storer BE , Sorror M , Diaconescu R , et al.   Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning . J Clin Oncol . 2005;23:1993–2003
  20. Gomez CR , Boehmer ED , Kovacs EJ . The aging innate immune system . Curr Opin Immunol . 2005;17:1–6
  21. Shlomchik WD , Couzens MS , Tang CB , McNiff J , Robert ME , Liu J , et al.   Prevention of graft versus host disease by inactivation of host antigen-presenting cells . Science . 1999;285:412–415
  22. Ordemann R , Hutchinson R , Friedman J , Burakoff SJ , Reddy P , Duffner U , et al.   Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease . J Clin Invest . 2002;109:1249–1256
  23. Akha A , Miller R . Signal transduction in the aging immune system . Curr Opin Immunol . 2005;17:1–6
  24. Goronzy J , Weyand CM . T cell development and receptor diversity during aging . Curr Opin Immunol . 2005;17:1–8
  25. Kollman C , Howe CW , Anasetti C , Antin JH , Davies SM , Filipovich AH , et al.   Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors (The effect of donor age) . Blood . 2001;98:2043–2051
  26. Alamo J , Shahjahan M , Lazarus HM , de Lima M , Giralt SA . Comorbidity indices in hematopoietic stem cell transplantation (A new report card) . Bone Marrow Transplant . 2005;36:475–479
  27. Sorror ML , Maris MB , Storb R , Baron F , Sandmaier BM , Maloney DG , et al.   Hematopoietic cell transplantation-specific comorbidity index (A new tool for risk assessment before allogeneic HCT) . Blood . 2005;
  28. Charlson ME , Pompei P , Ales KL , MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies (Development and validation) . J Chronic Dis . 1987;40:373–383
  29. Diaconescu R , Flowers CR , Storer B , Sorror ML , Maris MB , Maloney DG , et al.   Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors . Blood . 2004;104:1550–1558
  30. de Lima M , Anagnostopoulos A , Munsell M , Shahjahan M , Ueno N , Ippoliti C , et al.   Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome (Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation) . Blood . 2004;104:865–872
  31. Clift RA , Buckner CD , Appelbaum FR , Sullivan KM , Storb R , Thomas ED . Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia . Blood . 1998;92:1455–1456
  32. Feinstein LC , Sandmaier BM , Hegenbart U , McSweeney PA , Maloney DG , Gooley TA , et al.   Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission . Br J Haematol . 2003;120:281–288
  33. Childs R , Clave E , Contentin N , et al.   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation (Full donor T-cell chimerism precedes alloimmune responses) . Blood . 1999;94:3234–3241
  34. Slavin S , Nagler A , Naparstek E , Kapelushnik Y , Aker M , Cividalli G , et al.   Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases . Blood . 1998;91:756–763
  35. Giralt S , Estey E , Albitar M , van Besien K , Rondon G , Anderlini P , et al.   Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy (harnessing graft-versus-leukemia without myeloablative therapy) . Blood . 1997;89:4531–4536
  36. Aoudjane M , Labopin M , Gorin N , Shimoni A , Ruutu M , Kolb H , et al.   Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia (A retrospective survey from the acute leukemia party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)) . Leukemia . 2005;1–9 [Epub ahead of print:,]
  37. Alyea E , Kim H , Ho VT , Cutler C , Gribben J , DeAngelo D , et al.   Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic stem cell transplantation for patients older than 50 years of age . Blood . 2005;105:1810–1814
  38. Wallen H , Gooley T , Deeg HJ , Pagel JM , Press OW , Appelbaum FR , et al.   Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older . J Clin Oncol . 2005;23:3439–3446
  39. de Lima M , Couriel D , Thall PF , Wang X , Madden T , Jones R , et al.   Once-daily intravenous busulfan and fludarabine (Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS) . Blood . 2004;104:857–864
  40. de Lima M , Champlin R , Andersson B . Treatment of AML/MDS with allogeneic hematopoietic stem cell transplantation after intravenous busulfan-based conditioning therapy . Biol Blood Marrow Transplant Rev . 2005;15:10–11
  41. de Lima M , Couriel D , Ghosh S , Jones R , Shpall EJ , Giralt S , et al.   Outcomes of older patients with myeloid leukemias treated with myeloablative intravenous busulfan-based conditioning regimens and allogeneic blood or marrow transplantation . Blood . 2005;106:660a; (abstr)
  42. Shimoni A , Kroger N , Zabelina T , Ayuk F , Hardan I , Yeshurun M , et al.   Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies (Older age is no longer a contraindication when using reduced intensity conditioning) . Leukemia . 2005;19:7–12
  43. Nagler A . Myeloablative conditioning using IV busulfan reduces toxicity to the level observed in low-intensity conditioning regimens (dose does matter) . Biol Blood Marrow Transplant . 2005;15:8–9
  44. Cutler CS , Lee SJ , Greenberg P , Deeg HJ , Perez WS , Anasetti C , et al.   A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes (Delayed transplantation for low-risk myelodysplasia is associated with improved outcome) . Blood . 2004;104:579–585
  45. Estey E . The Thompson/Luger article reviewed . Oncology . 2005;19:542–543
  46. Tibes R , de Lima M , Estey E , Pierce S , Champlin R , Giralt S . Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoietic stem cell transplantation (HSCT) in elderly patients with AML and MDS . Blood . 2005;106:2892a; (abstr)
  47. Scott BL , Storer B , Loken MR , Storb R , Appelbaum FR , Deeg HJ . Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome . Biol Blood Marrow Transplant . 2005;11:65–73
  48. Liang Y , Van Zant G , Szilvassy SJ . Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells . Blood . 2005;106:1479–1487
  49. Park Y , Gerson S . DNA repair defects in stem cell function and aging . Annu Rev Med . 2005;56:508
  50. Parmar S , Fernandez-Vina M , Liu P , Cano P , Andersson B , Munsell M , et al.   Influence of allele level HLA typing on unrelated donor (UD) transplantation for high-risk myeloid leukemias . Blood . 2005;106:2916a; (abstr)
  51. Chakraverty R , Peggs K , Chopra R , Milligan D , Kottaridis PD , Verfuerth S , et al.   Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen . Blood . 2002;99:1071–1078
  52. van Besien K , Artz A , Smith D , Cao D , Rich L , Gooley D , et al.   Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome . J Clin Oncol . 2005;23:5728–5738
  53. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantion for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulfan and alemtuzumab (FBC) conditioning . Blood . 2004;104:1616–1623
  54. Martino R , Perez-Simon J , Moreno E , Queralto J , Caballero D , Mateos M , et al.   Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning . Biol Blood Marrow Transplant . 2005;11:437–447
  55. Maris MB , Niederwieser D , Sandmaier BM , Storer B , Stuart M , Maloney D , et al.   HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies . Blood . 2003;102:2021–2030
  56. Bertz H , Patthoff K , Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia . J Clin Oncol . 2003;21:1480–1484
  57. Wallen H , Gooley TA , Deeg HJ , Pagel JM , Press OW , Appelbaum FR , et al.   Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older . J Clin Oncol . 2005;23:3439–3446
  58. Spyridonidis A , Bertz H , Ihorst G , Grullich C , Finke J . Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (>= 60 years) with active myeloid malignancies (letter) . Blood . 2005;105:4147–4148
  59. Wong R , Giralt SA , Martin T , Couriel DR , Anagnostopoulos A , Hosing C , et al.   Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years . Blood . 2003;102:3052–3059
  60. Schmid C , Schleuning M , Ledderose G , Tischer J , Kolb H . Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor-lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome . J Clin Oncol . 2005;23:5675–5687

PII: S0037-1963(06)00021-7

doi: 10.1053/j.seminhematol.2006.01.004

Seminars in Hematology
Volume 43, Issue 2 , Pages 107-117 , April 2006

Article Tools

* Image Usage & Resolution